ESC 365 - Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase

Open Access

Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase

Session: Advances in heart failure therapeutics

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Professor M. Petrie (Glasgow, GB)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Professor Mark C Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

52 presentations

11 followers

4 more presentations in this session

Refining definitions of severe and advanced heart failure: insight from the swedish heart failure registry to optimize trial design and improve referral to advanced therapies

Speaker: Doctor F. Guidetti (Bern, CH)

Association between neutrophil-to-lymphocyte ratio, exercise capacity and outcomes in patients with heart failure and reduced ejection fraction

Speaker: Doctor E. Rodenas Alesina (Toronto, CA)

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

Speaker: Doctor P. Tolomeo (Glasgow, GB)

Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on patients' needs and perceptions

Speaker: Ms R. Monroe (Charlotte, US)

Access the full session

Advances in heart failure therapeutics

Speakers: Professor M. Petrie, Doctor F. Guidetti, Doctor E. Rodenas Alesina, Doctor P. Tolomeo, Ms R. Monroe

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources